Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprepitant/bupivacaine/meloxicam - Heron Therapeutics

Next Previous
Drug Profile

Aprepitant/bupivacaine/meloxicam - Heron Therapeutics

Alternative Names: Aprepitant/meloxicam/bupivacaine - Heron Therapeutics; Bupivacaine/aprepitant/meloxicam - Heron Therapeutics; Bupivacaine/meloxicam/aprepitant - Heron Therapeutics; HTX-034; Meloxicam/aprepitant/bupivacaine - Heron Therapeutics; Meloxicam/bupivacaine/aprepitant - Heron Therapeutics

Latest Information Update: 14 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heron Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Analgesics; Anilides; Anti-inflammatories; Antidepressants; Antiemetics; Antipyretics; Antirheumatics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Local anaesthetics; Morpholines; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pipecolic acids; Piperidines; Small molecules; Thiazines; Thiazoles; Triazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Neurokinin 1 receptor antagonists; Peptide hydrolase inhibitors; Sodium channel antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Postoperative pain

Most Recent Events

  • 31 Dec 2023 HTX 034 has patent protection in USA, Albania, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Mexico, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey and the United Kingdom
  • 29 Mar 2023 Suspended - Phase-II for Postoperative pain in USA (Topical) prior to March 2023
  • 19 Sep 2022 Phase-II clinical trials in Postoperative pain in USA (Topical) (Heron Therapeutics pipeline; September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top